| Sep 6 2016 |
IP Part 2: Protect Your Automotive Intellectual Property or Else |
Varnum LLP |
| Sep 6 2016 |
Four Key Changes to Antitrust Guidelines for Licensing of Intellectual Property—DOJ, FTC Invite Comments |
ArentFox Schiff LLP |
| Sep 6 2016 |
PTO Litigation Center Report – September 6, 2016 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Sep 6 2016 |
Delaware District Court Upholds Eligibility Of Personalized Medicine Method Claims For FANAPT |
Foley & Lardner LLP |
| Sep 6 2016 |
Brexit: International and EU Legal Frameworks Affected and Unaffected |
Greenberg Traurig, LLP |
| Sep 2 2016 |
Design Patents and Copyrights for Designs on Useful Articles |
Foley & Lardner LLP |
| Sep 2 2016 |
Need for Illumination of Maximum Recovery Rule Warrants Interlocutory Appeal |
Proskauer Rose LLP |
| Sep 2 2016 |
September 2016 Update - gTLD Sunrise Periods Now Open |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Sep 2 2016 |
Scent Trademarks: Have Sense About Scents |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Sep 2 2016 |
PTO Litigation Center Report – September 2, 2016 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Sep 1 2016 |
Apotex v Wyeth Explores Structural Obviousness |
Schwegman, Lundberg & Woessner, P.A. |
| Sep 1 2016 |
Proposed Update of the Antitrust Guidelines for Licensing Intellectual Property: FTC and DOJ Seek Public Comment |
Michael Best & Friedrich LLP |
| Sep 1 2016 |
ITC Declines to File Petition for Certiorari – CAFC Holding ITC Does Not Have Jurisdiction over Digital Imports Stands |
Mintz |
| Sep 1 2016 |
PTO Litigation Center Report – September 1, 2016 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Aug 31 2016 |
Brexit and Your Trade Marks – Some Practical Questions Answered |
Faegre Drinker |
| Aug 31 2016 |
Protect Your Automotive Industry Intellectual Property or Else: IP Part 2 |
Varnum LLP |
| Aug 30 2016 |
Ninth Circuit to District Court on Trademarks: Pucker Up for a Remand |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
Estoppel Prevents Second IPR Petition Even When New References Were Missed By First Search |
Foley & Lardner LLP |
| Aug 30 2016 |
Summary Judgment Ruling Affirmed as Bench Trial Decision |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
PTAB Grants Patent Owner Motion to Request Certificate of Correction |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
“Providing . . . Information” to Medical Providers Is Not Given Patentable Weight |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
PTO Litigation Center Report – August 30, 2016 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Aug 30 2016 |
Retroactive Estoppel: Acting as Real Party in Interest May Import Estoppel Effects from Earlier-Filed Petitions |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
PTO Initiates Post-Prosecution Pilot Program |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
Biosimilar FDA Approvals on Horizon As More States Enact Substitution Laws |
Mintz |
| Aug 30 2016 |
Federal Circuit Will Review PTAB Rules for Claim Amendments in AIA Reviews |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
“Crazy Horse” Trademark Still Going Crazy in Las Vegas |
McDermott Will & Schulte LLP |
| Aug 30 2016 |
Federal Circuit Rules Device Patent Claims Not Limited by Specification Description, Not Invalid for Lack of Written Description |
Covington & Burling LLP |
| Aug 30 2016 |
Help USPTO Leverage Prior Art From Related Patent Applications |
Foley & Lardner LLP |
| Aug 29 2016 |
Indefiniteness of Means-Plus-Function Claims |
McDermott Will & Schulte LLP |
| Aug 29 2016 |
Indirect Infringement Not Overcome by Objective Strength of Non-Infringement Case |
McDermott Will & Schulte LLP |
| Aug 29 2016 |
Prevailing Party Before PTAB May Not Appeal |
McDermott Will & Schulte LLP |
| Aug 29 2016 |
Patent Infringement Claim Exempts Related Counterclaims from Mandatory Arbitration |
McDermott Will & Schulte LLP |
| Aug 29 2016 |
Concerted Actions with Sister Company in Finland Result in Delaware Jurisdiction |
McDermott Will & Schulte LLP |
| Aug 29 2016 |
Biologics Price Competition and Innovation Act 180-Day Notice of Intent to Market a Biosimilar Is Required, Enforceable by Injunction |
McDermott Will & Schulte LLP |
